Additionally, the ADAURA trial in EGFR-positive NSCLC and the ALINA trial in ALK-positive NSCLC have highlighted the survival benefits of targeted adjuvant therapy in eligible patients10,11. The gene discussed is ALK; the disease is non-small cell lung carcinoma.